Skip to content
ClinCalc Pro
Menu
H2-receptor antagonist Pregnancy: Tests in animals and clinical evidence reveal no hazards, but cimetidine crosses the placental barrier and is excreted in milk. Use during pregnancy and lactation should be avoided unless considered essential by the physician.

Cimetidine

Brand names: Tagamet

Cimetidine is a histamine H2-receptor antagonist used to reduce gastric acid secretion in conditions such as peptic ulcer disease, gastro-oesophageal reflux and dyspepsia.

Auto-extracted from the source labelling — not yet independently clinician-verified. These values were distilled from the UK SPC (or the US label where noted) but have not had a clinician sign-off. Confirm against the current SmPC before prescribing.

Adult dose

Dose: 400 mg
Route: Oral (tablets swallowed with a drink of water)
Frequency: Twice daily, with breakfast and at bedtime (usual dosage)
Max: The total daily dose should not normally exceed 2.4 g
Duodenal or benign gastric ulceration: a single daily dose of 800 mg at bedtime is recommended. Other effective regimens: 200 mg three times a day with meals plus 400 mg at bedtime (1.0 g/day) and, if inadequate, 400 mg four times a day (1.6 g/day) with meals and at bedtime. Treat initially for at least four weeks (six weeks in benign gastric ulcer); ulcers not healed by then usually heal after a further course. For longer-term treatment the dose may be reduced to 400 mg at bedtime, or 400 mg in the morning and at bedtime. Relapse prevention in benign peptic ulcer disease: usually 400 mg at bedtime (400 mg morning and bedtime has also been used). Oesophageal reflux disease: 400 mg four times a day with meals and at bedtime for four to eight weeks to heal oesophagitis and relieve symptoms. Very high gastric acid secretion (e.g. Zollinger-Ellison syndrome): may need 400 mg four times a day, or occasionally more. Prophylaxis of haemorrhage from stress ulceration in seriously ill patients: 200-400 mg every four to six hours. Risk of acid aspiration syndrome: 400 mg orally 90-120 minutes before induction of general anaesthesia, or at the start of labour in obstetric practice; while the risk persists a dose of up to 400 mg may be repeated at four-hourly intervals, up to the usual daily maximum of 2.4 g, with the usual precautions to avoid acid aspiration. Short bowel syndrome (e.g. after substantial resection for Crohn's disease): the usual dosage range according to individual response. To reduce degradation of pancreatic enzyme supplements: 800-1600 mg a day in four divided doses, one to one and a half hours before meals. Elderly: normal adult dosage unless renal function is markedly impaired. Malignancy should be excluded by endoscopy and biopsy before treating gastric ulceration, since cimetidine can relieve symptoms and help superficial healing of gastric cancer.

Paediatric dose

Route: Oral
Frequency: Total daily dose given in divided doses
Max: No paediatric maximum is stated in the source
SPC §4.2 states: experience in children is less than that in adults. Children more than one year old: 25-30 mg/kg body weight per day in divided doses may be administered. Infants under one year old: use is not yet fully evaluated; 20 mg/kg body weight per day in divided doses has been used. A single dosePerKg value has deliberately not been asserted because the source states a range and the under-1-year figure is described as 'has been used' rather than recommended. Verify against a children's formulary before prescribing.

Dose adjustments

Renal

Reduce the dose according to creatinine clearance (SPC §4.4): CrCl 0-15 mL/min — 200 mg twice a day; 15-30 mL/min — 200 mg three times a day; 30-50 mL/min — 200 mg four times a day; over 50 mL/min — normal dosage. Cimetidine is removed by haemodialysis but not to any significant extent by peritoneal dialysis.

Dose auto-extracted from UK Summary of Product Characteristics (SPC) via the eMC; US FDA prescribing information (openFDA / DailyMed) — cross-check; US labelling may differ from UK — not yet clinician-verified. Always confirm against the product SmPC and your local formulary before prescribing.

Contraindications

  • Hypersensitivity to the active substance or to any of the excipients

Side effects

  • Headache and dizziness (common)
  • Diarrhoea (common)
  • Skin rashes (common)
  • Myalgia and tiredness (common)
  • Gynaecomastia and reversible impotence (uncommon)
  • Confusional states, depression, hallucinations (uncommon) — usually in elderly or ill patients, reversible within a few days of withdrawal

Interactions

  • Cimetidine can prolong the elimination of drugs metabolised by oxidation in the liver (e.g. diazepam, propranolol)
  • Oral anticoagulants / coumarins — close monitoring of prothrombin time recommended; dose reduction may be necessary
  • Phenytoin — close monitoring recommended; dose reduction may be necessary
  • Theophylline — dosage adjustment may be required when starting or stopping cimetidine
  • Intravenous lidocaine (lignocaine) — clinically significant interaction
  • Drugs with a narrow therapeutic index generally — absorption, metabolism or renal excretion may be affected, needing dose adjustment or discontinuation
  • Drug treatments or illnesses that could cause falls in blood cell count — H2-receptor antagonism could potentiate this effect

Clinical monograph

How it works

It competitively blocks histamine H2 receptors on gastric parietal cells, reducing both basal and stimulated gastric acid secretion.

Prescribing in practice

  • Cimetidine is a potent inhibitor of several cytochrome P450 enzymes and raises plasma concentrations of many drugs, including warfarin, phenytoin and theophylline, so co-prescribing requires careful review and dose adjustment.
  • Doses should be reduced in renal impairment, and it can cause confusion in elderly or seriously ill patients.
  • Acid suppression may mask the symptoms of gastric cancer, so alarm features should be investigated before attributing them to benign dyspepsia.

Monitoring

Routine laboratory monitoring is not required, but monitor the effects of interacting drugs, such as the INR in patients taking warfarin, and review renal function where relevant.

Counselling the patient

  • Tell your prescriber about all your other medicines, as interactions are common.
  • Report any persistent difficulty swallowing, weight loss or signs of bleeding.
  • Let your team know if you feel confused, particularly if you are elderly or unwell.

Evidence & guidelines

H2-receptor antagonists are an established acid-suppressing option for peptic ulcer disease and reflux, though proton pump inhibitors are generally preferred first-line in NICE guidance.

Reference: Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.